UPDATE: Abiomed (ABMD) Tops Q4 EPS by 1c, FY Revenue Guidance Misses Estimate

Abiomed (NASDAQ: ABMD) reported Q4 EPS of $1.09, ex-gain, $0.01 better than the analyst estimate of $1.08. Revenue for the quarter came in at $207 million versus the consensus estimate of $218.91 million.

The company is giving its fiscal year 2020 guidance for total revenues to be in the range of $900 million to $945 million, an increase of 17% to 23% over the prior year. The company is also giving its fiscal year 2020 guidance for GAAP operating margin to be in the range of 29% to 31%. The company plans to give another formal forecast for the fiscal year on the next earnings call.

(**Street sees FY20 revenue of $988.66 million)

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• The LGL Group (LGL) Misses Q2 EPS by 8c